JOURNAL OFVIROLOGY, Mar. 2007, p. 2138–2148 Vol. 81, No. 5 0022-538X/07/$08.00⫹0 doi:10.1128/JVI.02318-06
Copyright © 2007, American Society for Microbiology. All Rights Reserved.
The Human TRIM5
␣
Restriction Factor Mediates Accelerated
Uncoating of the N-Tropic Murine Leukemia Virus Capsid
䌤
Michel J. Perron,
1Matthew Stremlau,
1Mark Lee,
1Hassan Javanbakht,
1Byeongwoon Song,
1and Joseph Sodroski
1,2*
Department of Cancer Immunology and AIDS, Dana-Farber Cancer Institute, Division of AIDS, Harvard Medical School,
Boston, Massachusetts 02115,1and Department of Immunology and Infectious Diseases, Harvard School of
Public Health, Boston, Massachusetts 021152
Received 23 October 2006/Accepted 20 November 2006
The host cell factors TRIM5␣huand Fv-1 restrict N-tropic murine leukemia virus (N-MLV) infection at an
early postentry step before or after reverse transcription, respectively. Interestingly, the identity of residue 110 of the MLV capsid determines susceptibility to both TRIM5␣huand Fv-1. In this study, we investigate the fate
of the MLV capsid in cells expressing either the TRIM5␣huor Fv-1 restriction factor. The expression of
TRIM5␣hu, but not Fv-1, specifically promoted the premature conversion of particulate N-MLV capsids within
infected cells to soluble capsid proteins. The TRIM5␣hu-mediated disassembly of particulate N-MLV capsids
was dependent upon residue 110 of the viral capsid. Furthermore, the deletion or disruption of TRIM5␣hu
domains necessary for potent N-MLV restriction completely abrogated the disappearance of particulate N-MLV capsids observed with wild-type TRIM5␣hu. These results suggest that premature disassembly of the
viral capsid contributes to the restriction of N-MLV infection by TRIM5␣hu, but not by Fv-1.
Intracellular restriction factors can govern the species-spe-cific tropism of a broad range of retroviruses. Early studies identified the Friend virus susceptibility factor 1 (Fv-1) locus as a mouse determinant governing the ability of mouse strains to be infected by murine leukemia viruses (MLV) and to subse-quently develop leukemia (17). Two major alleles ofFv-1have been identified: Fv-1n, which renders NIH mice resistant to
B-tropic MLV (B-MLV) infection but susceptible to N-tropic (N-MLV) infection, andFv-1b, which renders BALB/c mice
resistant to N-MLV but susceptible to B-MLV infection (4, 10). Fv-1 is a dominant, saturable restriction factor that inhibits MLV infection following reverse transcription of the viral RNA but prior to the integration of viral DNA into the cellular genome (14). The Fv-1 protein is related to retroviral capsid proteins (14). The viral determinant of susceptibility to Fv-1 restriction has been mapped to residue 110 of the MLV capsid (7, 16). Currently, the mechanism by which Fv-1 restricts MLV infection is unknown.
More recently, rhesus monkey TRIM5␣ (TRIM5␣rh) and
human TRIM5␣(TRIM5␣hu) were identified as intracellular
restriction factors capable of blocking human immunodefi-ciency virus type 1 (HIV-1) and N-MLV infection, respectively, in the cells of these primate species (11, 15, 24, 33, 38). TRIM5␣ restricts HIV-1 and N-MLV at an early postentry step prior to reverse transcription (2, 3, 6, 12, 19, 30, 36). Interestingly, arginine 110 of the N-MLV capsid determines sensitivity to TRIM5␣hu-mediated restriction (24, 36).
Replac-ing the arginine residue at position 110 of the N-MLV capsid with the corresponding glutamic acid residue from B-MLV
generates a virus that can partially overcome TRIM5␣hu
re-striction. Conversely, replacement of glutamic acid 110 of the B-MLV capsid with arginine generates a virus that is suscep-tible to TRIM5␣hurestriction.
TRIM5␣is a member of the tripartite motif family of pro-teins and contains RING, B-box 2, and coiled-coil (RBCC) domains (25). At least three isoforms (␣,␥, and␦) of TRIM5 are generated by alternative splicing of the mRNA transcript. The longest of these isoforms, TRIM5␣, contains a C-terminal B30.2/SPRY domain. The role of each of the TRIM5␣ do-mains in retroviral restriction has been studied. For instance, removal of the RING domain partially abrogates TRIM5␣ restriction of either HIV-1 or N-MLV (13, 21, 33). Deletion of the B-box 2 domain completely eliminates the restricting abil-ity of TRIM5␣; the precise function of this domain remains unknown (13, 21). The coiled-coil domain has been shown to facilitate the multimerization of TRIM5␣, and its deletion completely abrogates HIV-1 and N-MLV restriction (1a, 18, 21). The TRIM5␣ B30.2 domain is the primary determinant for capsid recognition and restriction specificity (23, 26, 28, 35, 39). TRIM5␥, which lacks a B30.2 domain, and mutants of TRIM5␣with deleted B30.2 domains do not block HIV-1 or N-MLV infection (21, 33).
The exact mechanism by which TRIM5␣ restricts N-MLV infection is currently unknown. To investigate how TRIM5␣ mediates the restriction of retroviruses, we developed a fate-of-capsid assay that allowed us to monitor the steady-state levels of particulate retroviral capsids within an infected cell (34). This assay discriminates between cytosolic capsids that are potentially on the infection pathway and capsids that are nonspecifically endocytosed into the cell but do not enter the cytosol. The assay further distinguishes particulate capsids from smaller moieties in the cytosol of infected cells. In this study, we utilized the fate-of-capsid assay to explore the effects
* Corresponding author. Mailing address: Dana-Farber Cancer In-stitute, 44 Binney Street, JFB 824, Boston, MA 02115. Phone: (617) 632-3371. Fax: (617) 632-4338. E-mail: joseph_sodroski@dfci.harvard .edu.
䌤Published ahead of print on 29 November 2006.
2138
on November 8, 2019 by guest
http://jvi.asm.org/
of TRIM5␣huand Fv-1 expression on the integrity of
particu-late MLV capsids within restricted cells.
MATERIALS AND METHODS
Vectors, cell lines, and viruses.All cell lines were maintained in Dulbecco’s modified Eagle’s medium supplemented with 10% newborn calf serum and antibiotics. All stably transduced cell lines were generated using the pLPCX vector, selected using 3.0g/ml puromycin, and maintained in 1.0g/ml puro-mycin. All of the expressed TRIM proteins contain a hemagglutinin (HA) tag at the C terminus, with the exception of mouse 9230105E10, which contains an N-terminal HA tag. The C95A,⌬RING (⌬1–92),⌬B-box 2 (⌬95–127),⌬RING/ ⌬B-box 2 (⌬1–130),⌬Coiled-coil (⌬130–231) (⌬CC), and RBCC (⌬239–497) variants of TRIM5␣huwere generated in the pLPCX vector using PCR mutagen-esis. The Fv-1nand Fv-1bproteins are untagged; cDNA constructs were kindly provided by Jonathan P. Stoye. Recombinant MLV expressing green fluorescent protein (MLV-GFP) was prepared by calcium phosphate transfection of 293T cells with the pCIG Gag/Pol vector (5), an MLV vector expressing GFP, and pVPack-VSV-G at a weight ratio of 15:15:4, respectively. The pVPack-VSV-G plasmid expresses the vesicular stomatitis virus (VSV) G envelope glycoprotein, which mediates efficient entry into a variety of vertebrate cells (40). All MLV-GFP vectors were titrated onto 293T cells and normalized for infectivity based on a dilution of virus that yielded 50% infected cells.
A single-round infection assay using MLV-GFP.MDTF cells (2⫻104 ) stably transduced with either an empty LPCX vector or LPCX expressing HA-tagged TRIM5 or untagged Fv-1 were seeded onto a 24-well plate and incubated overnight at 37°C. Various doses of normalized N- or B-MLV–GFP were then diluted to 500l and added to the cells in the presence of 5.0g/ml Polybrene. After 16 h of incubation, the virus-containing medium was replaced with fresh medium and incubation continued for an additional 48 h. GFP-positive cells were then quantified using fluorescence-activated cell sorting (FACS).
Fate-of-capsid assay. Recombinant MLV virus-like particles (VLPs) were produced by calcium phosphate cotransfection of 293T cells with pCIGN, pCIGB, pCIGNBNN, or pCIGBNBB vector (5), along with pVPack-VSV-G, at a weight ratio of 15:4.
Stably transduced NIH 3T3 (1.5⫻106
) or MDTF (1.5⫻106
) cells expressing the different TRIM5 or Fv-1 variants were seeded in 80-cm2flasks. The following day, the cells were incubated with 5 to 10 ml (approximately 2.5⫻105
to 5.0⫻ 105transcriptase units) of N-, B-, NBNN-, or BNBB-MLV VLPs at 4°C for 30 min to allow viral attachment to the cells. The cells were then shifted to 37°C until they were harvested at various time points. For cells harvested at time points later than 4 h, the virus was removed after 4 h and replaced with fresh medium. The cells were washed three times using ice-cold phosphate-buffered saline (PBS) and detached by treatment with 1.0 ml of pronase (7.0 mg/ml in Dulbecco’s modified Eagle’s medium) for 5 min at 25°C. The cells were then washed three times with PBS. The cells were resuspended in 2.5 ml hypotonic lysis buffer (10 mM Tris-HCl, pH 8.0, 10 mM KCl, 1 mM EDTA, and one Complete protease inhibitor tablet) and incubated on ice for 15 min. The cells were lysed using 15 strokes in a 7.0-ml Dounce homogenizer with pestle B. Cellular debris was cleared by centrifugation for 3 min at 3,000 rpm. To allow assessment of the total input MLV p30 capsid protein, 100l of the cleared lysate was collected, made 1⫻in sodium dodecyl sulfate (SDS) sample buffer, and analyzed by SDS-polyacrylamide gel electrophoresis (PAGE) and Western blotting (see below). Then, 2.0 ml of the cleared lysate was layered onto a 50% sucrose (weight per volume) cushion in 1⫻PBS and centrifuged at 125,000⫻g
for 2 h at 4°C in a Beckman SW41 rotor. Following centrifugation, 100l of the topmost portion of the supernatant was collected and made 1⫻in SDS sample buffer; this sample is referred to as the soluble p30 fraction. The pellet was resuspended in 50l 1⫻SDS sample buffer and is referred to as the particulate p30 fraction. All samples were then subjected to SDS-PAGE and Western blotting (see below).
Some pilot experiments were conducted using sucrose cushions in which the sucrose concentration ranged from 45 to 70% (weight per volume).
Immunoblotting.HA-tagged TRIM5 variants were detected using the horse-radish peroxidase-conjugated 3F10 antibody. The MLV p30 protein was detected using a rat monoclonal antibody purified from the R187 hybridoma cell line (American Type Culture Collection).
Analysis of the N-MLV genome.Approximately 1.5⫻106
MDTF cells stably transduced with either an empty LPCX vector or an LPCX vector expressing TRIM5␣hu were seeded in 80-cm
2
flasks. The following day, the cells were incubated with 5.0 ml (approximately 2.5⫻105to 5.0⫻105reverse transcriptase units) of N-MLV–GFP at 4°C for 30 min to allow viral attachment to the cells. The cells were then shifted to 37°C for 2 h and analyzed using the fate-of-capsid
assay, as described above. The pellet was resuspended in either 50l 1⫻SDS sample buffer and subjected to SDS-PAGE and Western blotting (see above) or 250l RLT RNeasy lysis buffer, and total RNA was purified using an RNeasy Kit (QIAGEN). Reverse transcription (RT) PCR was performed using a QuantiTect SYBR Green RT-PCR kit (QIAGEN) and primers specific to the GFP gene in the vector (forward primer, GACGTAAACGGCCACAAGTT; reverse primer, GGTCTTGTAGTTGCCGTCGT). The reaction mixtures contained Quantitect SYBR Green, 500 nM of each primer, and 5.0l of purified RNA. The PCR conditions were 30 min at 50°C and 15 min at 95°C, followed by 40 cycles of 15 seconds at 95°C and 30 seconds at 72°C, on an MJ Research DNA Engine Opticon.
RESULTS
Establishment of an assay to investigate the postentry fate of MLV capsids in infected cells. We previously utilized the fate-of-capsid assay to demonstrate that a decrease in the level of particulate HIV-1 capsids is observed in the cytosol of cells expressing a restricting TRIM5␣protein (34). To investigate the fate of MLV capsids in infected cells, we developed an approach that would allow us to distinguish cytosolic MLV capsids that are potentially on the infection pathway from capsids that are nonspecifically endocytosed and that do not lead to infection of the cell. Because the density of endosomes is less than that of retroviral capsids, endosome-associated capsids can be separated from cytosolic capsids by density gradient centrifugation. To identify the appropriate sucrose concentrations that would allow discrimination between endo-somal and cytosolic capsids, we incubated MDTF cells with N-MLV and B-MLV that lacked envelope glycoproteins or that were pseudotyped with the VSV G envelope glycoprotein. Although the viruses lacking envelope glycoproteins can attach to cells and be endocytosed, the capsids of these viruses do not enter the cytosol because virus-host cell membrane fusion does not occur. Figure 1A (left) shows that postnuclear lysates from MDTF cells contain similar levels of the N-MLV capsid pro-tein, p30, following exposure to viruses with and without en-velope glycoproteins. Sedimentation through 45 to 55% su-crose solutions allowed separation of particulate capsids from endosomal capsids (Fig. 1A, right). Density gradient sedimen-tation through solutions of 60% or higher concentrations of sucrose resulted in decreased recovery of cytosolic particulate N-MLV capsids. The density of a 60% (weight per volume) sucrose solution, 1.23 g/ml, corresponds exactly to the reported density of Moloney MLV capsids (1).
The results obtained with B-MLV differed from those seen for N-MLV. The amounts of MLV p30 capsid proteins in the lysates of MDTF cells exposed to VSV G-pseudotyped B-MLV virions were typically within threefold of those observed in cells exposed to the VSV G-pseudotyped N-MLV virions (Fig. 1B, left). However, unlike the cytosolic N-MLV capsids, the cyto-solic B-MLV capsids did not sediment through 55% sucrose cushions (Fig. 1B, right). This result suggests that, under these conditions, cytosolic B-MLV capsids exhibit lower density or stability, or both, than N-MLV capsids. Based on these obser-vations, we employed 50% (weight per volume) sucrose cush-ions for our subsequent analyses of the fates of both N-MLV and B-MLV capsids after infection.
To investigate the effect of TRIM5␣hu expression in the
target cells on the fate of the N-MLV capsid, MDTF cells transduced with the empty LPCX vector or LPCX expressing TRIM5␣huwere incubated with N-MLV particles pseudotyped
on November 8, 2019 by guest
http://jvi.asm.org/
with VSV G glycoprotein or lacking envelope glycoproteins. Cell lysates cleared of nuclei and large debris were layered onto 50% sucrose cushions and centrifuged. The input lysates from the cells incubated with the virions lacking envelope glycoproteins, as well as with the VSV G-pseudotyped virions, contained detectable p30 capsid proteins (Fig. 1C). Particulate cytosolic capsids were readily detected 2 hours after infection of the control LPCX-transduced cells with VSV G-pseudotyped N-MLV. In comparison, by 2 hours after infection of TRIM5␣hu
-expressing cells with VSV G-pseudotyped N-MLV, the amount of cytosolic capsid that sedimented through the 50% sucrose cush-ion was greatly reduced. The supernatants that did not enter the 50% sucrose cushion were analyzed for the presence of the N-MLV capsid protein. Multiple 100-l samples were sequentially removed from the top of the supernatants and Western blotted for the p30 capsid protein. Figure 1C shows the results obtained for the uppermost layer of supernatants. The amount of the p30 capsid protein in this supernatant layer from the TRIM5␣hu -FIG. 1. Assay to follow the fate of the MLV capsid within infected cells. (A) MDTF cells transduced with an empty LPCX control vector were infected with either VSV G-pseudotyped (Env⫹) N-MLV or envelope-deficient (Env⫺) N-MLV virus-like particles for 4 h. Cell lysates were then prepared, and an aliquot was used for Western blotting with an antibody directed against the MLV p30 capsid protein (left). The remaining cell lysates were analyzed on gradients formed with the indicated concentrations of sucrose (weight per volume). The pellets were Western blotted using an antibody directed against the MLV p30 capsid protein. (B) MDTF cells transduced with an empty LPCX control vector were infected with either VSV G-pseudotyped (Env⫹) or envelope-deficient (Env⫺) N-MLV or B-MLV virus-like particles for 4 h. Cell lysates were then prepared and analyzed on gradients formed with the indicated concentrations of sucrose (weight per volume). The total input and pellets were Western blotted using an antibody directed against the p30 capsid protein. (C) MDTF cells stably transduced with either an empty LPCX control vector or an LPCX vector expressing TRIM5␣huwere infected with either VSV G-pseudotyped (Env⫹) or envelope-deficient (Env⫺)
N-MLV-GFP for 2 h and analyzed using the fate-of-capsid assay, as described in Materials and Methods. The total input, supernatants, and pellets were Western blotted using an antibody directed against the p30 capsid protein. (D) MDTF cells transduced with either an empty LPCX control vector or an LPCX vector expressing TRIM5␣huwere infected with either VSV G-pseudotyped (Env⫹) or envelope-deficient (Env⫺) N-MLV-GFP for
2 h and analyzed by the fate-of-capsid assay. The presence of viral RNA within the pelleted cores was detected by RT-PCR, as described in Materials and Methods. The amount of viral RNA in the pellet associated with the LPCX cells exposed to (Env⫹) N-MLV-GFP was standardized to 100% and set as a reference for comparison to the RNA levels associated with the LPCX-transduced cells exposed to (Env⫺) N-MLV-GFP and the TRIM5␣hu-expressing cells exposed to the (Env⫹) N-MLV-GFP. The error bars indicate standard deviations.
2140 PERRON ET AL. J. VIROL.
on November 8, 2019 by guest
http://jvi.asm.org/
expressing cells was greater than that seen for the LPCX-trans-duced control cells. Similar results were obtained for the addi-tional 100-l samples taken from sequentially lower layers of the supernatants (data not shown). The endosomal layer that bands immediately above the 50% sucrose cushion demonstrated high levels of p30 capsid protein, as well as the unprocessed p65 Gag precursor protein, for both the LPCX-transduced and TRIM5␣hu-expressing cells (data not shown). This endosomal
layer apparently contains immature virion particles, as well as mature virions that have not entered the cytosol. To avoid sampling this endosomal layer, we analyzed only the upper-most fraction of the supernatants in subsequent experiments. We conclude that, in TRIM5␣hu-expressing cells compared
with control cells, a reduction in the level of particulate capsids is accompanied by an increase in the amount of soluble capsid proteins in the cytosol. Note that, because only a fraction of the supernatant is sampled and analyzed, a quantitative conversion of capsid protein from the pellet to the supernatant is not expected. These results are consistent with a model in which TRIM5␣hu-mediated restriction of N-MLV infection is
acpanied by an accelerated conversion of particulate capsid com-plexes to smaller subunits in the cytosol. The major fraction of N-MLV capsid proteins detectable in TRIM5␣hu-expressing
cells did not exhibit evident changes in migration on SDS-polyacrylamide gels compared with capsid proteins derived from control cells. Thus, most N-MLV capsid proteins in TRIM5␣hu-expressing cells do not undergo extensive
posttrans-lational modifications (e.g., ubiquitylation or SUMOylation) that differ from those occurring in the control cells.
To document that viral RNA is associated with the particu-late capsids detected in the assay described above, the pellets from the sucrose density gradients were used for RNA extrac-tion. The extracted RNA was reverse transcribed and quanti-fied by real-time PCR. The amount of viral RNA detected by this method was proportional to the amount of p30 capsid protein pelleted from the lysates of TRIM5␣hu-expressing and
LPCX control cells exposed to envelope-deficient and VSV G-pseudotyped N-MLV virions (compare Fig. 1D with the pellet p30 in C). Thus, the capsids that sediment in this assay are associated with viral RNA.
Association of human TRIM5␣restriction with decreases in the amount of particulate N-MLV capsids in the cytosol.To examine the relationship between TRIM5␣hu-mediated
re-striction and the levels of particulate N-MLV capsids in the cytosol of infected cells, we applied the fate-of-capsid assay to MDTF and NIH 3T3 cells expressing different TRIM proteins and exposed to N-MLV and B-MLV. MDTF and NIH 3T3 cells expressing TRIM5␣hu, TRIM5␣rh, and the mouse TRIM
protein, 9230105E10, were studied (Fig. 2A). The mouse 9230105E10 protein is related to TRIM5 but is not ortholo-gous and does not restrict N-MLV infection. As shown in Fig. 2B, the expression of TRIM5␣hupotently restricted N-MLV in
MDTF cells, whereas only a modest level of restriction was observed in cells expressing TRIM5␣rh. The efficiency of
N-MLV infection of cells expressing the murine TRIM protein, 9230105E10, was comparable to that of control cells trans-duced with the empty LPCX vector. B-MLV infection was unaffected by the expression of any of the TRIM variants.
Using the fate-of-capsid assay, we analyzed the amounts of particulate capsids in the cytosol of MDTF and NIH 3T3 cells
expressing the various TRIM proteins. As shown in Fig. 2C, expression of the potently restricting TRIM5␣hu protein
re-sulted in a dramatic reduction in the amount of particulate cytosolic N-MLV capsids compared to the amount in the empty LPCX control cells. Importantly, this decrease in par-ticulate N-MLV capsid coincided with an increase in the amount of soluble p30 capsid protein within the supernatant. Only a slight reduction in the amount of particulate N-MLV capsids was observed in the cytoplasm of cells expressing the moderately restricting TRIM5␣rh protein. Expression of the
nonrestricting mouse 9230105E10 TRIM protein had no effect on the amount of particulate cytosolic N-MLV capsids recov-ered compared with the amount in control cells. The amount of particulate B-MLV capsids recovered from the cytosol of the MDTF and NIH 3T3 cells was generally less than that in the N-MLV capsids, despite similar amounts of input capsid. This may be related to differences in the density and/or stability of N-MLV and B-MLV cytosolic capsids, as discussed above. Expression of the TRIM variants had no significant effect on the amounts of particulate B-MLV capsids. In some experi-ments in which the amount of pelletable B-MLV p30 was low, minor variation in pelletable p30 was observed, but this was not reproducible. We conclude that the expression of TRIM5␣hu
results in restriction of N-MLV infection; accompanying this restriction are decreases in the levels of particulate N-MLV capsids and increases in the levels of soluble capsid protein in the cytosol.
Timing of the TRIM5␣hueffect on particulate cytosolic
N-MLV capsids.Studies examining the effects of cyclosporine A treatment have demonstrated that the owl monkey restriction factor, TRIMCyp, mediates HIV-1 restriction within 15 min of virus entry into the cell (22, 27). Furthermore, previous fate-of-capsid studies have demonstrated that TRIM5␣rhpromotes
the disappearance of particulate cytosolic HIV-1 capsids within 1 h after infection (34). These data suggest that TRIM proteins block retroviral infection shortly after virus entry into the cytoplasm. To determine how fast TRIM5␣hudecreases
the levels of particulate cytosolic N-MLV capsids, MDTF cells were incubated with VSV-G-pseudotyped N-MLV at 4°C and then the temperature was raised to 37°C to allow virus entry to occur. At various times after the temperature increase, the fate-of-capsid assay was performed. As shown in Fig. 3, par-ticulate N-MLV capsids were readily detectable in the cytosol of MDTF cells containing an empty LPCX vector within 15 min of the temperature increase. By contrast, the expression of TRIM5␣huresulted in decreases in the amounts of particulate
N-MLV capsids that were evident by 15 min after the temper-ature increase. TRIM5␣huexpression had no consistent effect
on the steady-state levels of particulate B-MLV capsids. We conclude that TRIM5␣hucan promote the disappearance of
particulate N-MLV capsids in the target cell cytoplasm within 15 min of infection.
Influence of residue 110 of the MLV capsid on TRIM5␣hu
-mediated decreases in the amounts of particulate capsids.
N-MLV susceptibility to TRIM5␣hurestriction is influenced by
arginine 110 of the viral capsid (24, 36). Replacement of this arginine with the corresponding residue of B-MLV, glutamic acid, creates NBNN-MLV, which partially escapes TRIM5␣hu
restriction (24, 36). Conversely, replacing glutamic acid 110 of B-MLV with the arginine found in the N-MLV capsid
on November 8, 2019 by guest
http://jvi.asm.org/
ates BNBB-MLV, which is susceptible to TRIM5␣hu
restric-tion (24, 36). To determine if there is a correlarestric-tion between the residue at position 110 of the MLV capsid and the amount of particulate capsid observed in the cytosol of restricted cells, we infected control or TRIM5␣hu-expressing MDTF or NIH 3T3
cells with N-, B-, NBNN-, and BNBB-MLV and performed the fate-of-capsid assay. As demonstrated in Fig. 4, viruses suscep-tible to TRIM5␣hurestriction, N- and BNBB-MLV, exhibited
levels of particulate capsids in cells expressing TRIM5␣hu
sig-nificantly lower than those seen in cells transduced with the empty LPCX vector. By contrast, only a modest decrease in the steady-state level of particulate NBNN-MLV capsids was ob-served in TRIM5␣hu-expressing cells, consistent with the
ob-servation that NBNN-MLV can partially escape TRIM5␣hu
restriction (24, 36). The expression of TRIM5␣huin NIH 3T3
or MDTF cells did not result in a relative decrease in the amounts of particulate B-MLV capsids. Of interest, when the input amount of p30 capsid protein is taken into consideration, a generalized decrease in the amounts of particulate capsids was observed in all cell lines infected with B- and NBNN-MLV compared to N- and BNBB-MLV-infected cells. We conclude that the TRIM5␣hu-mediated decrease in the level of
particu-late MLV capsids in the cytosol is dependent upon the arginine at position 110 of the viral capsid.
TRIM5␣hudomains are required to promote decreases in
the levels of particulate N-MLV capsids in the cytosol of cells.
Previous studies using deletion mutagenesis have identified the B-box 2, coiled-coil, and B30.2 domains as critical for the antiviral activity of TRIM5␣rh(13, 21). By contrast, deletion of
[image:5.585.106.474.66.450.2]the RING domain only partially reduces TRIM5␣rhantiviral FIG. 2. Effect of the expression of a restricting TRIM␣protein on the amounts of particulate N-MLV capsids in the cytosol of infected cells. (A) Steady-state expression levels of the TRIM proteins are shown. Lysates from MDTF or NIH 3T3 cells transduced with either an empty LPCX vector or LPCX vectors expressing HA-tagged TRIM proteins were subjected to Western blotting using an anti-HA antibody. The lysates were also blotted against-actin to control for total protein. “Mouse” refers to the mouse 9230105E10 protein, used here as a negative control. (B) MDTF cells transduced with LPCX vectors expressing the indicated TRIM proteins were infected with various doses of N-MLV-GFP or B-MLV-GFP. GFP-positive cells were quantified by FACS analysis. (C) MDTF or NIH 3T3 cells stably transduced with either an empty LPCX control vector or an LPCX vector expressing the indicated TRIM protein were infected with VSV G-pseudotyped N- or B-MLV virus-like particles for 4 h and analyzed using the fate-of-capsid assay, as described in Materials and Methods. Total input, supernatants, and pellets were Western blotted using an antibody directed against the p30 capsid protein. “Mouse” refers to the mouse 9230105E10 protein.
2142 PERRON ET AL. J. VIROL.
on November 8, 2019 by guest
http://jvi.asm.org/
activity (13, 21, 33). We wished to determine which TRIM5␣hu
domains are necessary for N-MLV restriction and whether these correlate with the TRIM5␣hudomains required to
me-diate decreases in the level of particulate N-MLV capsids in the cytosol of infected cells. To that end, we generated a series of TRIM5␣hudeletion mutants and measured their abilities to
restrict N- and B-MLV infection. As shown in Fig. 5A, MDTF cells expressing TRIM5␣huare very resistant to N-MLV
infec-tion. Deletion of the RING domain (TRIM5␣hu⌬RING)
re-duced the N-MLV inhibition approximately 10-fold, suggesting that the RING domain potentiates, but is not absolutely re-quired for, restriction. By contrast, deletion of the B-Box 2 (TRIM5␣hu⌬B-box), RING and B-box 2 (TRIM5␣hu⌬RING/
⌬B-box), coiled-coil (TRIM5␣hu⌬CC), or B30.2 (TRIM5␣hu
RBCC) domain resulted in TRIM5␣huproteins that had no
effect on N-MLV infection. B-MLV infection was unaffected
FIG. 3. Time course of TRIM5␣hu-induced loss of particulate N-MLV capsids in infected cells. MDTF cells transduced with either an empty
LPCX vector or an LPCX vector expressing TRIM5␣huwere incubated at 4°C for 30 min with either N-MLV (A) or B-MLV (B) virus-like particles.
The cells were then incubated at 37°C for the indicated times and analyzed using the fate-of-capsid assay. Total input, supernatants, and pellets were Western blotted using an antibody directed against the p30 capsid protein, as described in Materials and Methods.
FIG. 4. Influence of MLV capsid residue 110 on the TRIM5␣hu-mediated loss of particulate N-MLV capsids. NIH 3T3 and MDTF cells transduced
either with an empty LPCX vector or with a vector expressing TRIM5␣huwere infected with N-, B-, NBNN-, or BNBB-MLV virus-like particles for 4 h
and analyzed using the fate-of-capsid assay, as described in Materials and Methods. Total input, supernatants, and pellets were Western blotted using an antibody directed against the p30 capsid protein. The amount of pelleted p30 was quantified and normalized against total input p30. The percentage of particulate p30 in TRIM5␣hu-expressing cells compared to that in the control LPCX cells is provided at the bottom of the figure for each virus.
on November 8, 2019 by guest
http://jvi.asm.org/
by the expression of any of the TRIM5␣hudeletion variants.
We conclude that the B-box 2, coiled-coil, and B30.2 domains of TRIM5␣hu are essential for its anti-N-MLV activity; the
RING domain contributes significantly to the antiviral activity but is not absolutely essential.
Western blot analysis demonstrated that all of the TRIM5␣hudeletion mutants tested were expressed at least as
well as the wild-type TRIM5␣huprotein (Fig. 5B). As has been
reported previously for TRIM5␣rh(8, 13, 21), deletion of the
RING and/or B-box 2 domain of TRIM5␣huresulted in
in-creased steady-state levels of expression.
To identify which TRIM5␣hudomains are involved in
me-diating decreases in the levels of particulate cytosolic N-MLV capsids, we performed the fate-of-capsid assay using MDTF cells expressing the TRIM5␣hudeletion mutants. As observed
previously, the expression of wild-type TRIM5␣hugreatly
re-duced the amount of particulate N-MLV capsids in the cytosol of MDTF cells (Fig. 5C). Deletion of any TRIM5␣hudomain
severely compromised the ability of TRIM5␣hu to promote
[image:7.585.79.504.72.476.2]decreases in the level of particulate MLV capsids. An N-MLV vector lacking an envelope glycoprotein was included to ensure that endosomal p30 was not contaminating the cytosolic p30 fractions (34). The assay was repeated, using larger amounts (2.0 ml and 10.0 ml) of N-MLV VLPs, with similar
FIG. 5. Effects of deletion of the TRIM5␣hudomains on N-MLV restriction and levels of particulate N-MLV capsids in the cytosol of infected
cells. (A) MDTF cells transduced with LPCX vectors expressing wild-type TRIM5␣huor deletion mutants were infected with various doses of
N-MLV-GFP or B-MLV-GFP. GFP-positive cells were quantified using FACS analysis. (B) Steady-state expression levels of TRIM5 variants are shown. Lysates from MDTF cells transduced with either an empty LPCX vector or LPCX vectors expressing the indicated HA-tagged TRIM5␣hu
variants were subjected to Western blotting using an anti-HA antibody. The lysates were also blotted against-actin to control for total protein. (C) MDTF cells transduced with either an empty LPCX vector or vectors expressing the indicated TRIM5␣huvariants were infected with VSV
G-pseudotyped (Env⫹) N-MLV virus-like particles for 4 h and analyzed using the fate-of-capsid assay. Cells transduced with the empty LPCX vector were also incubated with N-MLV virus-like particles lacking envelope glycoproteins (Env⫺). Total input, supernatants, and pellets were Western blotted using an antibody directed against the MLV p30 capsid protein.
2144 PERRON ET AL. J. VIROL.
on November 8, 2019 by guest
http://jvi.asm.org/
results (data not shown). We conclude that deletion of any TRIM5␣hudomain necessary for potent restriction of N-MLV
also compromises the ability of TRIM5␣huto promote a
de-crease in the level of particulate N-MLV capsids in the cytosol of infected cells.
Deletion of the TRIM5␣B-box 2 domain completely abro-gates HIV-1 and N-MLV restriction yet has no effect on TRIM5␣multimerization or interaction with the viral capsid (13, 18, 21, 34). These observations suggest that the B-box 2 domain may mediate an effector function critical for retroviral restriction. We examined the consequences of a single amino acid change within the TRIM5␣huB-box 2 domain for N-MLV
restriction and cytosolic levels of N-MLV capsid particles. Previously, we identified an alanine substitution within the TRIM5␣rhB-box 2 domain that completely abrogated HIV-1
restriction while maintaining wild-type TRIM5␣rhexpression
levels and subcellular localization (13). The analogous TRIM5␣huvariant [TRIM5␣hu(C95A)] was generated by
sub-stitution of alanine for cysteine 95 in the B-box 2 domain. As shown in Fig. 6A, TRIM5␣hu(C95A) was expressed in MDTF
cells at a level at least as great as that of the wild-type TRIM5␣huprotein. Despite this efficient level of expression,
TRIM5␣hu(C95A) was completely unable to restrict N-MLV
infection (Fig. 6B). Furthermore, the expression of TRIM5␣hu
(C95A) had no effect on the amount of particulate cytosolic N-MLV capsids compared with the levels observed in the control cells transduced with the empty LPCX vector (Fig. 6C). By con-trast, expression of the wild-type TRIM5␣huprotein resulted in a
decrease in the amount of particulate N-MLV capsids and a concomitant increase in the amount of soluble capsid proteins in the cytosol of infected cells. These data suggest that the conserved cysteine at position 95 of the B-box 2 domain is critical for both TRIM5␣hu-mediated processes: restriction of N-MLV infection
and the conversion of particulate cytosolic N-MLV capsids into soluble forms of capsid.
Effect of Fv-1 expression on the amount of particulate MLV capsid in the cytosol of infected cells.Although TRIM5␣and Fv-1 restrictions are both influenced by residue 110 of the MLV capsid, they target different steps of the MLV life cycle: TRIM5␣ restricts N-MLV prior to reverse transcription, whereas Fv-1 restricts N- or B-MLV following the completion of reverse transcription (24, 36). To determine whether Fv-1 restriction modulates the amount of particulate cytosolic MLV capsids, we first generated MDTF cells stably expressing Fv-1n
or Fv-1band examined their abilities to support N- or B-MLV
infection. As shown in Fig. 7A, the expression of Fv-1npotently
restricted B-MLV infection but had no effect on N-MLV in-fection. Conversely, the expression of Fv-1bpotently restricted
N-MLV infection but had no effect on B-MLV infection. The potency of Fv-1 restriction in MDTF cells allows exam-ination of the effect of Fv-1 restriction on the level of partic-ulate MLV capsids following infection. As shown in Fig. 7B, equivalent levels of particulate N- or B-MLV capsids were recovered after 16 h from the cytosol of MDTF cells trans-duced with an empty LPCX vector or vectors expressing Fv-1n
or Fv-1b. By contrast, expression of TRIM5␣
huin the MDTF
[image:8.585.309.523.79.533.2]cells resulted in a complete loss of particulate capsids from the cytosol, consistent with the results described above. As ob-served previously, compared with the amount of particulate N-MLV capsids, significantly less particulate B-MLV capsid
FIG. 6. Effect of a single amino acid change in the TRIM5␣hu
B-box 2 domain on N-MLV restriction and the loss of particulate N-MLV capsids. (A) Steady-state expression levels of TRIM5 variants are shown. Lysates from MDTF cells transduced with either an empty LPCX vector or LPCX vectors expressing HA-tagged TRIM5␣huor
TRIM5␣hu(C95A) were subjected to Western blotting using an
anti-HA antibody. The lysates were also blotted against-actin to control for total protein. (B) MDTF cells transduced with either an empty LPCX vector or LPCX vectors expressing TRIM5␣hu or
TRIM5␣hu(C95A) were infected with various doses of N-MLV-GFP
or B-MLV-GFP. GFP-positive cells were quantified using FACS anal-ysis. (C) MDTF cells expressing either an empty LPCX vector or LPCX vectors expressing TRIM5␣huor TRIM5␣hu(C95A) were
in-fected with VSV G-pseudotyped (Env⫹) N-MLV virus-like particles for 4 h and analyzed using the fate-of-capsid assay. The control cells transduced with the empty LPCX vector were also incubated with N-MLV virus-like particles without envelope glycoproteins (Env⫺). Total input, supernatants, and pellets were Western blotted using an antibody directed against the p30 capsid protein.
on November 8, 2019 by guest
http://jvi.asm.org/
protein was recovered after centrifugation of cytosolic lysates. Similar results were also obtained 4 h postinfection (data not shown). These results suggest that the expression of a restrict-ing Fv-1 protein in MDTF cells exerts little or no effect on the amounts of particulate MLV capsids in the cytosol of infected cells.
DISCUSSION
In this study, we utilized a recently developed fate-of-capsid assay (24, 36) to demonstrate that TRIM5␣huexpression
rap-idly decreases the steady-state levels of particulate N-MLV capsids in the cytosol of the infected cell. The study of TRIM proteins from different species, TRIM5␣humutants, and MLV
capsid variants revealed a close correlation between the re-striction of virus infection and decreases in the amounts of particulate viral capsids in the cytosol. Hypothetically, two models might account for the TRIM5␣hu-associated decreases
in the amounts of particulate N-MLV capsids observed in the fate-of-capsid assay: (i) TRIM5␣hudegrades the N-MLV
cap-sid or (ii) TRIM5␣hupromotes the rapid disassembly of the
N-MLV capsid. Several lines of evidence suggest that neither ubiquitin modification nor degradation of the retroviral capsid is an essential element of the TRIM5␣restriction mechanism. First, treatment of TRIM5␣rh-expressing cells with
proteaso-mal inhibitors does not relieve HIV-1 restriction (5a, 22, 34, 37). Moreover, N-MLV infection was efficiently blocked by TRIM5␣hu in a Chinese hamster E36 cell line expressing a
temperature-sensitive E1 ubiquitin ligase, even at the nonper-missive temperature (22). In our study and a previous study (34), no modified forms or cleavage products of the N-MLV p30 capsid protein were observed specifically in TRIM5␣hu
-expressing cells. Most importantly, in TRIM5␣hu-expressing
cells compared with control cells, an increase in soluble p30 typically accompanied the observed decrease in particulate p30, suggesting that TRIM5␣hupromotes the conversion of the
particulate viral core into slower-sedimenting forms of p30.
Taken together, these data argue that ubiquitin ligation, pro-teasome degradation, and/or massive degradation of the viral core are not essential components of TRIM5␣restriction.
Our data support a model in which TRIM5␣hu mediates
N-MLV restriction by promoting the rapid disassembly of the viral capsid. Previous studies have hinted at the existence of an optimal stability of the retroviral core for HIV-1 infection (9, 29). Changes in the HIV-1 capsid protein that alter the stability of the viral core in either a positive or negative direction have deleterious effects on the efficiencies of early infection events (9). These data suggest that the retroviral core is a metastable structure that is stable enough to allow reverse transcription yet sufficiently labile to facilitate the uncoating necessary for subsequent steps in the viral life cycle. TRIM5␣humay
accel-erate the normal uncoating process or promote aberrant dis-assembly of the N-MLV core. Either of these processes might result in aborted reverse transcription and infection. Prema-ture disassembly of the retroviral capsid may expose other viral proteins and the genome to ubiquitin-dependent or indepen-dent degradation pathways. Wu et al. recently reported that treatment of TRIM5␣rh-expressing cells with proteasome
in-hibitors allowed HIV-1 to complete reverse transcription, even though the cells remained restricted for HIV-1 infection (37). If the viral cDNA detected in their study is on the infection pathway, the result suggests that the TRIM5␣rh restriction
mechanism does not necessarily rely upon the degradation of the viral genome.
Interestingly, particulate B-MLV capsids were inefficiently recovered from the cellular cytosol by our fate-of-capsid assay. Moreover, the efficiency with which we recovered particulate MLV capsids was influenced by the identity of residue 110 of the MLV capsid (Fig. 4). One explanation for these observa-tions is that N- and B-MLV have evolved relatively stable or unstable capsids, respectively. The intrinsic stability of the MLV capsid could govern viral susceptibility to intracellular restriction factors, possibly explaining why N-MLV and not B-MLV is targeted by a diverse group of TRIM molecules (3,
FIG. 7. Effect of Fv-1 expression on the amount of particulate MLV capsids recovered in the fate-of-capsid assay. (A) MDTF cells transduced with LPCX vectors expressing either Fv-1nor Fv-1bwere infected with various doses of N-MLV-GFP or B-MLV-GFP. GFP-positive cells were
quantified by FACS analysis. The experiment was repeated with comparable results; the data from a single experiment are shown. (B) MDTF cells expressing either an empty LPCX vector or LPCX vectors expressing TRIM5␣hu, Fv-1
n, or Fv-1bwere incubated with VSV G-pseudotyped N-MLV
or B-MLV virus-like particles for 4 h. The virus-containing medium was then replaced with fresh medium, and the cells were lysed 16 h later. Cell lysates were analyzed using the fate-of-capsid assay. Total input, supernatants, and pellets were Western blotted using an antibody directed against the p30 capsid protein.
2146 PERRON ET AL. J. VIROL.
on November 8, 2019 by guest
http://jvi.asm.org/
31, 32, 36). For example, a virus that has evolved a relatively stable capsid might be more susceptible to factors that pro-mote rapid capsid destabilization than a virus that normally tolerates a less stable capsid. Alternatively, stable N-MLV cap-sids could provide a more suitable recognition surface for TRIM molecules. TRIM5␣hu has been reported to bind
N-MLV, but not B-N-MLV, capsids (28). Furthermore, Shi and Aiken demonstrated that only stable HIV-1 virus-like particles are able to compete for TRIM5␣(29). Destabilization of the HIV-1 core by mutagenesis abrogates the ability of these virus-like particles to saturate TRIM5␣restriction, suggesting that the stability of the retroviral core can govern the efficiency of interaction with TRIM5␣.
TRIM5␣rh-mediated restriction of HIV-1 infection involves
multiple domains: the B30.2 domain specifies recognition of the incoming viral capsids, the coiled coil promotes the mul-timerization of TRIM5␣ molecules, and an effector region (RING and B-box 2 domains), although not needed for viral capsid binding, contributes to full restriction. Our deletion analysis of the TRIM5␣hudomains demonstrated that the
B-box 2, coiled-coil, and B30.2 domains are essential for medi-ating N-MLV restriction. Furthermore, for this set of TRIM5␣ deletion mutants, we observed a correlation between restric-tion of infecrestric-tion and the ability to promote decreases in the levels of particulate N-MLV capsids in the cytosol of infected cells. Our assay for restriction of N-MLV infections may be more sensitive than the fate-of-capsid assay, based upon the observation that deletion of the TRIM5␣hu RING domain
abrogated activity in the latter assay but only partially attenu-ated virus restriction.
A recent study has demonstrated that the overexpression of theFv-1ballele in human TE671 cells can compete with
endogenous TRIM5␣hu(20). Indeed, the expression of Fv-1b
allows N-MLV to overcome TRIM5␣hu restriction and
be-come blocked at a post-reverse transcription step, characteris-tic of Fv-1 restriction (20). These data suggest that both TRIM5␣huand Fv-1 interact with the MLV capsid shortly after
viral entry but restrict MLV infection either before or after reverse transcription, respectively. In this study, we demon-strated that the expression of TRIM5␣hu causes a rapid
de-crease in particulate N-MLV capsids within the cytoplasm as early as 15 min postinfection. Conversely, no change in the level of particulate MLV capsids was observed in the cytosol of Fv-1n- or Fv-1b-expressing cells at either 4 or 16 h after
infec-tion. These data suggest that Fv-1 and TRIM5␣hu restrict
MLV infection through two distinct mechanisms.
Further studies examining early postentry events and how these events are modulated by host factors will expand our knowledge of retroviral biology and the mechanism of TRIM5␣ restriction.
ACKNOWLEDGMENTS
We thank Yvette McLaughlin and Elizabeth Carpelan for manu-script preparation and Kathleen McGee-Estrada and Alan Engelman for assistance with the RT-PCR assay.
We thank the National Institutes of Health (AI063987 and a Center for AIDS Research Award, AI60354), the International AIDS Vaccine Initiative, the Bristol-Myers Squibb Foundation, and the late William F. McCarty-Cooper. H.J. was supported by a fellowship from the Canadian Institutes of Health Research and by the William A. Haseltine Foundation for the Arts and Sciences. M.S. was supported
by a National Defense Science and Engineering Fellowship and is a Fellow of the Ryan Foundation.
REFERENCES
1.Andersen, K. B., H. A. Diep, and A. Zedeler.2006. Murine leukemia virus transmembrane protein R-peptide is found in small virus core-like com-plexes in cells. J. Gen. Virol.87:1583–1588.
1a.Berthoux, L., S. Sebastian, D. M. Sayah, and J. Luban.2005. Disruption of human TRIM5␣antiviral activity by nonhuman primate orthologues. J. Vi-rol.79:7883–7888.
2.Besnier, C., Y. Takeuchi, and G. Towers.2002. Restriction of lentivirus in monkeys. Proc. Natl. Acad. Sci. USA99:11920–11925.
3.Besnier, C., L. Ylinen, B. Strange, A. Lister, Y. Takeuchi, S. P. Goff, and G. J. Towers.2003. Characterization of murine leukemia virus restriction in mam-mals. J. Virol.77:13403–13406.
4.Best, S., P. Le Tissier, G. Towers, and J. P. Stoye.1996. Positional cloning of the mouse retrovirus restriction gene Fv1. Nature382:826–829.
5.Bock, M., K. N. Bishop, G. Towers, and J. P. Stoye.2000. Use of a transient assay for studying the genetic determinants of Fv1 restriction. J. Virol.
74:7422–7430.
5a.Chatterji, U., M. D. Bobardt, P. Gashill, D. Sheeter, H. Fox, and P. A. Gallay.2006. TRIM5␣accelerates degradation of cytosolic capsid associated with productive HIV-1 entry. J. Biol. Chem.281:37025–37033.
6.Cowan, S., T. Hatziioannou, T. Cunningham, M. A. Muesing, H. G. Gottlinger, and P. D. Bieniasz.2002. Cellular inhibitors with Fv1-like activity restrict human and simian immunodeficiency virus tropism. Proc. Natl. Acad. Sci. USA99:11914–11919.
7.DesGroseillers, L., and P. Jolicoeur.1983. Physical mapping of the Fv-1 tropism host range determinant of BALB/c murine leukemia viruses. J. Virol.48:685–696.
8.Diaz-Griffero, F., X. Li, H. Javanbakht, B. Song, S. Welikala, M. Stremlau, and J. Sodroski.2006. Rapid turnover and polyubiquitylation of the retro-viral restriction factor TRIM5. Virology349:300–315.
9.Forshey, B. M., U. von Schwedler, W. I. Sundquist, and C. Aiken.2002. Formation of a human immunodeficiency virus type 1 core of optimal stability is crucial for viral replication. J. Virol.76:5667–5677.
10.Hartley, J. W., W. P. Rowe, and R. J. Huebner.1970. Host-range restrictions of murine leukemia viruses in mouse embryo cell cultures. J. Virol.5:221– 225.
11.Hatziioannou, T., D. Perez-Caballero, A. Yang, S. Cowan, and P. D. Bieniasz.
2004. Retrovirus resistance factors Ref1 and Lv1 are species-specific variants of TRIM5␣. Proc. Natl. Acad. Sci. USA101:10774–10779.
12.Himathongkham, S., and P. A. Luciw.1996. Restriction of HIV-1 (subtype B) replication at the entry step in rhesus macaque cells. Virology219:485– 488.
13.Javanbakht, H., F. Diaz-Griffero, M. Stremlau, Z. Si, and J. Sodroski.2005. The contribution of RING and B-box 2 domains to retroviral restriction mediated by monkey TRIM5␣. J. Biol. Chem.280:26933–26940. 14.Jolicoeur, P., and E. Rassart.1980. Effect of Fv-1 gene product on synthesis
of linear and supercoiled viral DNA in cells infected with murine leukemia virus. J. Virol.33:183–195.
15.Keckesova, Z., L. M. Ylinen, and G. J. Towers.2004. The human and African green monkey TRIM5␣genes encode Ref1 and Lv1 retroviral restriction factor activities. Proc. Natl. Acad. Sci. USA101:10780–10785.
16.Kozak, C. A., and A. Chakrabarti.1996. Single amino acid changes in the murine leukemia virus capsid protein gene define the target of Fv1 resis-tance. Virology225:300–305.
17.Lilly, F.1970. Fv-2: identification and location of a second gene governing the spleen focus response to Friend leukemia virus in mice. J. Natl. Cancer Inst45:163–169.
18.Mische, C. C., H. Javanbakht, B. Song, F. Diaz-Griffero, M. Stremlau, B. Strack, Z. Si, and J. Sodroski.2005. Retroviral restriction factor TRIM5␣is a trimer. J. Virol.79:14446–14450.
19.Munk, C., S. M. Brandt, G. Lucero, and N. R. Landau.2002. A dominant block to HIV-1 replication at reverse transcription in simian cells. Proc. Natl. Acad. Sci. USA99:13843–13848.
20.Passerini, L. D., Z. Keckesova, and G. J. Towers.2006. Retroviral restriction factors Fv1 and TRIM5␣act independently and can compete for incoming virus before reverse transcription. J. Virol.80:2100–2105.
21.Perez-Caballero, D., T. Hatziioannou, A. Yang, S. Cowan, and P. D. Bieniasz.
2005. Human tripartite motif 5␣domains responsible for retrovirus restriction activity and specificity. J. Virol.79:8969–8978.
22.Perez-Caballero, D., T. Hatziioannou, F. Zhang, S. Cowan, and P. D. Bieniasz.
2005. Restriction of human immunodeficiency virus type 1 by TRIM-CypA occurs with rapid kinetics and independently of cytoplasmic bodies, ubiquitin, and proteasome activity. J. Virol.79:15567–15572.
23.Perron, M. J., M. Stremlau, and J. Sodroski.2006. Two surface-exposed elements of the B30.2/SPRY domain as potency determinants of N-tropic murine leukemia virus restriction by human TRIM5␣. J. Virol.80:5631– 5636.
24.Perron, M. J., M. Stremlau, B. Song, W. Ulm, R. C. Mulligan, and J. Sodroski.2004. TRIM5␣lpha mediates the postentry block to N-tropic
on November 8, 2019 by guest
http://jvi.asm.org/
rine leukemia viruses in human cells. Proc. Natl. Acad. Sci. USA101:11827– 11832.
25.Reymond, A., G. Meroni, A. Fantozzi, G. Merla, S. Cairo, L. Luzi, D. Riganelli, E. Zanaria, S. Messali, S. Cainarca, A. Guffanti, S. Minucci, P. G. Pelicci, and A. Ballabio. 2001. The tripartite motif family identifies cell compartments. EMBO J.20:2140–2151.
26.Sawyer, S. L., L. I. Wu, M. Emerman, and H. S. Malik.2005. Positive selection of primate TRIM5␣identifies a critical species-specific retroviral restriction domain. Proc. Natl. Acad. Sci. USA102:2832–2837.
27.Sayah, D. M., E. Sokolskaja, L. Berthoux, and J. Luban.2004. Cyclophilin A retrotransposition into TRIM5 explains owl monkey resistance to HIV-1. Nature430:569–573.
28.Sebastian, S., and J. Luban.2005. TRIM5␣selectively binds a restriction-sensitive retroviral capsid. Retrovirology2:40.
29.Shi, J., and C. Aiken. 2006. Saturation of TRIM5␣-mediated restriction of HIV-1 infection depends on the stability of the incoming viral capsid. Virology350:493–500.
30.Shibata, R., H. Sakai, M. Kawamura, K. Tokunaga, and A. Adachi.1995. Early replication block of human immunodeficiency virus type 1 in monkey cells. J. Gen. Virol.76:2723–2730.
31.Si, Z., N. Vandegraaff, C. O’Huigin, B. Song, W. Yuan, C. Xu, M. Perron, X. Li, W. A. Marasco, A. Engelman, M. Dean, and J. Sodroski.2006. Evolution of a cytoplasmic tripartite motif (TRIM) protein in cows that restricts ret-roviral infection. Proc. Natl. Acad. Sci. USA103:7454–7459.
32.Song, B., H. Javanbakht, M. Perron, D. H. Park, M. Stremlau, and J. Sodroski.2005. Retrovirus restriction by TRIM5␣variants from Old World and New World primates. J. Virol.79:3930–3937.
33.Stremlau, M., C. M. Owens, M. J. Perron, M. Kiessling, P. Autissier, and J. Sodroski.2004. The cytoplasmic body component TRIM5␣restricts HIV-1 infection in Old World monkeys. Nature427:848–853.
34.Stremlau, M., M. Perron, M. Lee, Y. Li, B. Song, H. Javanbakht, F. Diaz-Griffero, D. J. Anderson, W. I. Sundquist, and J. Sodroski.2006. Specific recognition and accelerated uncoating of retroviral capsids by the TRIM5␣ restriction factor. Proc. Natl. Acad. Sci. USA103:5514–5519.
35.Stremlau, M., M. Perron, S. Welikala, and J. Sodroski.2005. Species-specific variation in the B30.2(SPRY) domain of TRIM5␣determines the potency of human immunodeficiency virus restriction. J. Virol.79:3139–3145. 36.Towers, G., M. Bock, S. Martin, Y. Takeuchi, J. P. Stoye, and O. Danos.
2000. A conserved mechanism of retrovirus restriction in mammals. Proc. Natl. Acad. Sci. USA97:12295–12299.
37.Wu, X., J. L. Anderson, E. M. Campbell, A. M. Joseph, and T. J. Hope.
2006. Proteasome inhibitors uncouple rhesus TRIM5␣ restriction of HIV-1 reverse transcription and infection. Proc. Natl. Acad. Sci. USA
103:7465–7470.
38.Yap, M. W., S. Nisole, C. Lynch, and J. P. Stoye.2004. Trim5␣protein restricts both HIV-1 and murine leukemia virus. Proc. Natl. Acad. Sci. USA
101:10786–10791.
39.Yap, M. W., S. Nisole, and J. P. Stoye.2005. A single amino acid change in the SPRY domain of human Trim5␣leads to HIV-1 restriction. Curr. Biol.
15:73–78.
40.Yee, J. K., T. Friedmann, and J. C. Burns.1994. Generation of high-titer pseudotyped retroviral vectors with very broad host range. Methods Cell Biol.43:99–112.
2148 PERRON ET AL. J. VIROL.
